Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes

Details

Instance of

clinical trial

Start time

3 November 2017

End time

28 November 2018

Country

Canada, Hungary, Poland, United Kingdom

Main subject

fatty liver disease

clinical trial phase

phase II clinical trial

maximum age

75

minimum age

18

number of participants

44

study type

interventional study

title

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ISIS 484137 (IONIS-DGAT2Rx, an Antisense Inhibitor of Diacylglycerol Acyltransferase 2) Administered Once-Weekly for 13 Weeks in Adult Patients With Type 2 Diabetes